Background -In canine epitheliotropic cutaneous T-cell lymphoma (ECTCL), neoplastic cells cause skin lesions and potentially metastasize to lymph nodes, blood and other organs. Murine models are potentially valuable for elucidating the molecular mechanisms responsible for regulation of ECTCL cell migration.
Introduction
Epitheliotropic cutaneous T-cell lymphoma (ECTCL) accounted for 11.84% of all canine lymphomas and 33.49% of canine T-cell lymphomas in one review. 1 Canine ECTCL is characterized by the proliferation of epitheliotropic cells and rapid progression with multiple patches, plaques, nodules and ulcers. 2 With progression of the disease, some dogs with ECTCL develop systemic metastasis to the lymph nodes, blood and other organs. 2 Immunophenotypically, malignant cells express CD3 in 100% and CD8 in 82.6% of dogs with ECTCL. 2 Lomustine is a recommended treatment for dogs with ECTCL; however, its efficacy is frequently low. 3 The prognosis of canine ECTCL is very poor, with a median survival of 6 months. 4 The cause of death is assumed to be septicaemia elicited by skin lesions or the failure of multiple organs caused by systemic metastasis in some cases. 5 Therefore, the molecular mechanisms responsible for ECTCL cell migration to skin or other organs need to be elucidated for the development of novel treatments.
The migration of cells is regulated by the interaction between chemokines and chemokine receptors. 6 Accordingly, cells express a set of chemokine receptors that influence their homing sites. Skin-homing lymphocytes express CC chemokine receptor (CCR) 4, 7 whereas T lymphocytes and dendritic cells express CCR7, which facilitates their migration to lymph nodes via lymphatic vessels. 8 Chemokine receptors have been implicated in the pathogenesis of human and canine ECTCL; CCR4 and CCR7 are expressed on the malignant cells of ECTCL patients. 9, 10 Furthermore, a chemotaxis assay indicated that CCR4 and CCR7 promote the migration of human ECTCL cell lines. 11, 12 In canine ECTCL the transcription levels of CCR4 and CCR7 were significantly higher in skin lesions than in normal skin, 13 suggesting that these receptors facilitate the migration of neoplastic cells into the skin and systemic metastases, respectively. Appropriate murine models are needed to prove this hypothesis; however, there are currently no laboratory models of canine ECTCL.
A cell line of canine ECTCL termed EO-1 has been established where cells express CD3 and CD8, similar to malignant cells in dogs with ECTCL.
14 Transcription analyses also have demonstrated that EO-1 cells transcribe CCR4 and CCR7.
14 These findings suggest that it could be possible to develop a novel murine model using mice xenografted with EO-1 cells. In the present study, we conducted a phenotypic analysis of NOD.CB17-Prkdc scid / J (NOD SCID) mice into which EO-1 cells were injected subcutaneously.
Methods and materials

Cell line
The ECTCL cell line EO-1 was cultured in 75 cm 2 flasks in RPMI 1640 medium (Sigma; St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (Biological Industries; Beit HaEmek, Israel), 1% penicillin/streptomycin (Sigma), and 2 mM L-glutamine (Sigma). EO-1 cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 without any growth factors or feeder cells. The culture medium was changed three times each week.
Xenograft
NOD SCID mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). They were maintained under specified pathogen-free conditions and fed autoclaved food and water. All procedures were approved by the Institutional Animal Care and Use Committee of our university (protocol #17003). A total of 1 9 10 8 EO-1 cells were subcutaneously injected into four mice (8-week-old females) under anaesthesia with isoflurane (Pfizer; Tokyo, Japan). The mice were monitored daily after injection and sacrificed approximately four weeks after the xenograft implantation. Peripheral blood was collected in a heparin-containing syringe by cardiac puncture. The morphology of white blood cells was assessed by May-Gr€ unwald Giemsa staining. Skin, lymph nodes, spleen, lung, liver, heart, kidney, stomach, small intestine, caecum and large intestine were fixed in 10% neutral buffered formalin and embedded in paraffin for histopathological and immunohistochemical analysis.
Histopathology and immunohistochemistry
Paraffin-embedded tissue sections (3 lm) were stained with haematoxylin and eosin. For immunohistochemical analysis, tissue sections (3 lm) were pretreated in an antigen retrieval solution (Dako; Glostrup, Denmark) by autoclaving at 121°C for 15 min and were subsequently probed with either rabbit anti-human CD3 15 (C7930, Sigma) or normal rabbit IgG (Wako; Osaka, Japan). After overnight incubation at 4°C, sections were treated with the EnVision+ System-horseradish peroxidase (HRP)-labelled polymer (Dako). The chromogen 3,3 0 -diaminobenzidine (DAB, Dako) was used for the visualization of immunolabelling, followed by counterstaining with haematoxylin.
Flow cytometric analysis
White blood cells were isolated from peripheral blood using lysing buffer (BD Biosciences; Franklin Lakes, NJ, USA), followed by an incubation with fluorescein isothiocyanate (FITC)-conjugated mouse anti-canine CD3 (clone CA17.2A12, Bio-Rad Laboratories; Hercules, CA, USA), allophycocyanin (APC)-conjugated rat anti-canine CD8 (clone YCATE55.9, Bio-Rad Laboratories) and phycoerythrin (PE)-conjugated mouse anti-human CCR4 (clone 1G1, BD Biosciences) 
Results
Between 25 and 29 days after the xenograft, all mice developed a solid mass, erythema, scales, erosions or ulcers in the skin into which EO-1 cells had been injected (Figure 1a) . The histopathological analysis indicated the infiltration of epitheliotropic malignant cells in the epithelium of hair follicles (Figure 1b,c) . These cells were positively stained with the anti-CD3 antibody (Figure 1d) . No malignant cells were detected in nonlesional skin (data not shown). A soft nodule formation was observed in the subcutis where EO-1 cells had been injected, ranging in size from 2.2 to 2.8 cm diameter in all mice (Figure 2a) . Erythema, scales, erosions or ulcers also were noted on the mass lesion. Splenomegaly and lymphadenopathy (axially, inguinal and iliac lymph nodes) also were noted in all mice (Figure 2b,c) . The histopathological analysis indicated the infiltration of malignant cells into spleen, lymph nodes (axially, inguinal and iliac), lung and liver (Figure 2d ), which was demonstrated by positive staining with anti-CD3 antibody (Figure 2e ). The cells were large lymphoblast-like cells that had migrated from vessels. In these organs, tissue destruction was also noted which might have been No malignant cells were detected in sections from the heart, kidney, stomach, small intestine, caecum and large intestine (Table 1) . Atypical lymphocytes were detected in peripheral blood (Figure 3a) . Morphological analysis revealed polymorphic round, oval or irregularly shaped cells. The cytoplasm was basophilic with a perinuclear halo. The nuclei were round or irregularly shaped, often lobulated and indented, with diffusely compact chromatin. Flow cytometric analysis of peripheral blood (n = 2) demonstrated that 95.5 AE 1.2% of lymphocytes were positive for canine CD3 (Figure 3b) , which was co-expressed with CCR4 and CD8 in 78.6 AE 9.8% of CD3 + cells (Figure 3c ).
Discussion
In the present study, NOD SCID mice xenografted with EO-1 cells developed skin lesions such as solid masses, erythema, scales, erosions or ulcers. Histopathological analysis showed that malignant cells only infiltrated the skin into which EO-1 cells had been injected. These cells also infiltrated various tissues besides the skin. This is a significant feature of EO-1 cells because systemic metastasis was not observed in mice xenografted with other CD8 + canine lymphoma cells (UL-1 and CLK) 23 or human ECTCL (including My-La, HUT78 and HH) cell lines. 24 Hence, mice xenografted with EO-1 cells may be useful for revealing the pathogenesis of systemic metastasis in canine ECTCL. In humans, malignant cells were present in lymphatic vessels but not peripheral blood, suggesting that ECTCL cells initially spread via the lymphatic system. 25 EO-1 cells transcribed CCR7, 
+ Presence of the malignant cells, À Absence of the malignant cells.
which facilitates homing to lymph vessels, similar to canine and human ECTCL cells; 10,13 therefore, EO-1 cells may have metastasized via lymphatic vessels in the present study. Additional analyses including the knockdown of CCR7 on EO-1 cells are needed in order to clarify the mechanisms responsible for metastasis to multiple organs.
Mogamulizumab (KW-0761), a humanized anti-CCR4 monoclonal antibody, is used in the treatment of human ECTCL. 26 Mogamulizumab has been shown to eliminate ECTCL cells via antibody-dependent cellular cytotoxicity. 26 Mogamulizumab is the first approved and clinically tested antibody against a chemokine receptor of cancer cells. 26 However, response rates were 36.8% and 38% in phase I and II studies, respectively, indicating that therapeutic efficacy is limited to a minority of ECTCL cases. 27, 28 There are other anti-chemokine receptor monoclonal antibodies currently being screened in laboratory or pre-clinical phases. Therefore, mice xenografted with EO-1 cells may contribute to evaluations of therapeutic efficacy and the identification of molecular targets for the treatment for ECTCL.
In conclusion, mice xenografted with EO-1 cells developed skin lesions with systemic metastasis, which have not been found with other canine and human ECTCL cell lines used to xenograft mice. 29, 30 Therefore, this xenograft mouse model may be useful not only for understanding the pathophysiology of ECTCL, but also for the development of novel treatments. a b c 
